Picture of CONCORD DRUGS logo

538965 CONCORD DRUGS Share Price

0.000.00%
in flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapNeutral

Momentum

Relative Strength (%)
1m+3.1%
3m-6.75%
6m-2.4%
1yr+0.71%
Volume Change (%)
10d/3m-49.42%
Price vs... (%)
52w High-37.06%
50d MA+4.75%
200d MA+1.59%

Growth & Value

12m Forecast RollingIndustryMarket
PE Ratio (f)n/a
PEG Ratio (f)n/a
EPS Growth (f)n/a
Dividend Yield (f)n/a
Valuation (ttm)IndustryMarket
Price to Book Value1.17
Price to Tang. Book1.17
Price to Free Cashflow75.48
Price to Sales0.93
EV to EBITDA11.89

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital8.31%
Return on Equity3.15%
Operating Margin7.62%

Financial Summary

Year End 31st MarUnit201920202021202220232024E2025ECAGR / Avg
Total RevenueIN₹m480.77513.39513.57589.56520.81n/an/a0.11%
Operating Profitm
Net Profitm
EPS Reported
Diluted Normalised EPS
EPS Growth%+25.53-27.47+23.16+294.33-41.98n/an/an/a
PE Ratiox
PEG
Profitability
Operating Margin%
ROA%
ROCE%
ROE%
Cashflow
Op. Cashflow ps
Capex ps
Free Cashflow ps
Dividends
Dividend ps
Dividend Growth%
Dividend Yield%
Dividend Coverx
Balance Sheet
Cash etcm
Working Capitalm
NFAm
Net Debtm
Book Valuem
Diluted Weighted Average Sharesm
Book Value ps

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Mar 202431st Mar 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of CONCORD DRUGS EPS forecast chart

Profile Summary

Concord Drugs Limited is an India-based pharmaceutical company. The principal activity of the Company is to manufacture licensed drugs based on the formulations approved. The Company offers finished pharmaceutical formulations, such as injectables (small volume parenteral, dry powders), tissue bio-adhesive, tablets, capsules, liquid orals (syrup and suspension) and dry syrups (powder). The Company also provides ready-to-fill pellets and multiple unit pellet system (MUPS). Its injectables include Amikacin Injection, Aceclofenac Injection, Artemether Injection, Adenosine Injection, and others. Iso Amyl 2-Cyano Acrylate is a tissue bio-adhesive. Its pellets are categorized as gastrointestinal drug pellets, cardiovascular drug pellets, respiratory drug pellets, anti-obesity drug pellets, anti-depressant drug pellets, central nervous system drug pellets, urological drug pellets, anti-microbial, anti-infective and adjuvant drugs pellets, taste mask drug pellets/powder, and others.

Directors

Last Annual
March 31st, 2023
Last Interim
December 31st, 2023
Incorporated
January 24th, 1995
Public Since
February 23rd, 2015
Sector
Pharmaceuticals
Industry
Healthcare
Exchange
in flag iconBombay Stock Exchange
Shares in Issue
10,000,000

538965 Share Price Performance

Upcoming Events for 538965

Similar to 538965

Picture of Achyut Healthcare logo

Achyut Healthcare

in flag iconBombay Stock Exchange

Picture of Adline Chem Lab logo

Adline Chem Lab

in flag iconBombay Stock Exchange

Picture of MPS Pharmaa logo

MPS Pharmaa

in flag iconBombay Stock Exchange

Picture of Albert David logo

Albert David

in flag iconBombay Stock Exchange

Picture of Ambalal Sarabhai Enterprises logo

Ambalal Sarabhai Enterprises

in flag iconBombay Stock Exchange

FAQ